Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

Launched by UNIVERSITY HOSPITAL, GHENT · Sep 5, 2019

Keywords

ClinConnect Summary

The BIOLOPTIM-BRO clinical trial is studying the medication brodalumab, which is used to treat moderate-to-severe psoriasis, a chronic skin condition. This trial aims to find out how effective measuring the levels of brodalumab in the blood can be in determining the right dosage for patients. Currently, brodalumab is given in a standard dose to everyone, which might lead to some patients getting too much or too little of the medication. By understanding the right blood levels needed for treatment, the researchers hope to improve how this medication is used and make it more effective for patients.

To participate in this trial, you must have a specific type of psoriasis called chronic plaque-type psoriasis and be aged 18 or older. You will need to sign a consent form to show that you understand the study and agree to take part. Throughout the study, you can expect to have your blood tested multiple times to check the levels of brodalumab. However, if you are pregnant, nursing, or have a different type of psoriasis, you will not be eligible to join. This study is a great opportunity for those looking to help improve treatments for psoriasis while potentially benefiting from personalized care based on their individual response to the medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis
• • 2. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
• Exclusion Criteria:
• • 1. Participants who have currently a predominant nonplaque form of psoriasis
• • 2. Participants who are pregnant, nursing or planning a pregnancy
• • 3. Participants who are unable or unwilling to undergo multiple venapunctures
• • 4. Participants who are treated according to a different dosing schedule than standard dosing of brodalumab